haemaccel registered trademark type intravenous colloid used prevention treatment shock associated reduction effective circulating blood volume due hemorrhage loss plasma burns peritonitis pancreatitis crush injuries loss water electrolytes persistent vomiting diarrhea haemaccel contains degraded gelatin used alternative human albumin solution starch supportive treatment ascites following procedure paracentesis polygelin excreted via kidneys plasma halflife three six hours increased hours patients kidney damage adverse drug reactions observed cases mainly due histamine release drop blood pressure bronchospasm skin involvement haemaccel also marketed emagel italy polygeline china solucel venezuela originally brought market hoechst ag later acquired piramal enterprises drug article relating blood blood forming organs stub help wikipedia expanding ithttpsenwikipediaorgwikihaemaccel